Nothing Compares to U-padacitinib

Seema A Patil^{1

2}, Raymond K Cross¹

Affiliations

¹ Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
² Department of Medicine, Division of Gastroenterology and Hepatology, Veteran's Affairs Maryland Health Care System, Baltimore, Maryland, USA.

Editorial

Seema A Patil et al. Am J Gastroenterol. 2023.

. 2023 Sep 1;118(9):1556-1557.

doi: 10.14309/ajg.0000000000002378. Epub 2023 May 25.

Seema A Patil^{1

2}, Raymond K Cross¹

¹ Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
² Department of Medicine, Division of Gastroenterology and Hepatology, Veteran's Affairs Maryland Health Care System, Baltimore, Maryland, USA.

No abstract available

Comment on

Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
Ahuja D, Murad MH, Ma C, Jairath V, Singh S. Ahuja D, et al. Am J Gastroenterol. 2023 Sep 1;118(9):1618-1625. doi: 10.14309/ajg.0000000000002263. Epub 2023 Mar 29. Am J Gastroenterol. 2023. PMID: 36976548

1. Dahlhamer JM, Zammitti EM, Ward BW, et al. Prevalence of inflammatory bowel disease among adults aged ≥18 years—United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65(42):1166–9.
1. Rubin D, Ananthakrishnan A, Siegel C, et al. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroetnerol 2019;114(3):384–413.
1. Peyrin-Biroulet L, Van Assche G, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Dig Liver Dis 2016;48:601–7.
1. Ahuja D, Murad MH, Ma C, et al. Comparative speed of early symptomatic remission with advanced therapies for moderate-severe ulcerative colitis: A systematic review and network meta-analysis. Am J Gastroenterol 2023;118(9):1618–25.
1. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2019;17(1):139–47.